Close

Aegis Capital Downgrades Acadia Pharma (ACAD) to Hold; Sees Nuplazid as Key, but Valuation Now Full

Go back to Aegis Capital Downgrades Acadia Pharma (ACAD) to Hold; Sees Nuplazid as Key, but Valuation Now Full